Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model

S. D. Shnyder, P. A. Cooper, George Pettit, J. W. Lippert, M. C. Bibby

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Background: The tubulin depolymerising drug Combretastatin A-1 phosphate (CA1P), a water-soluble derivative of combretastatin A-1, has been recently shown to have a better efficacy in experimental models than the clinically active, close structural analogue, combretastatin A-4 phosphate (CA4P). Previous studies with CA4P in combination with standard anti-cancer agents have demonstrated improved efficacy relative to the standard agents. Materials and Methods: In this study the synergistic effects of administering CA1P in combination with cisplatin (CPL) in a well-differentiated transplantable murine colon model (MAC 29) was evaluated. Results: CA1P at 100mgkg-1 significantly potentiated the anti-tumour effects of CPL. The effect with CPL was similar to that seen for CA1P at its maximum tolerated dose (MTD) alone. Conclusion: These data demonstrate that the combination of CA1P and CPL has significant preclinical antitumour activity against a transplantable murine adenocarcinoma model that is related to the antivascular effects of CA1P.

Original languageEnglish (US)
Pages (from-to)1619-1623
Number of pages5
JournalAnticancer Research
Volume23
Issue number2 B
Publication statusPublished - Mar 2003

    Fingerprint

Keywords

  • Anti-vascular effects
  • Combination chemotherapy
  • Combretastatins
  • MAC murine tumour model

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shnyder, S. D., Cooper, P. A., Pettit, G., Lippert, J. W., & Bibby, M. C. (2003). Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Research, 23(2 B), 1619-1623.